INOVIO to Present at Upcoming Scientific Conference
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines, has announced its participation in the World Congress of Electroporation on September 18, 2024, in Rome, Italy. Trevor Smith, VP of Preclinical R&D at INOVIO, will deliver an oral presentation titled 'Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA® electroporation technology' at 3:20pm CET.
This presentation aligns with INOVIO's focus on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company plans to make the abstract available on its website after the presentation, providing insights into their innovative approach using CELLECTRA® electroporation technology for DNA-encoded antibodies.
INOVIO (NASDAQ:INO), un'azienda biotecnologica specializzata nella medicina basata sul DNA, ha annunciato la sua partecipazione al World Congress of Electroporation il 18 settembre 2024, a Roma, Italia. Trevor Smith, VP della R&D Preclinica di INOVIO, presenterà un intervento orale intitolato 'Sviluppo di anticorpi sintetici codificati da DNA lanciati in vivo utilizzando la tecnologia di elettroporazione CELLECTRA®' alle 15:20 CET.
Questa presentazione è in linea con l'impegno di INOVIO nello sviluppo di medicinali a base di DNA per malattie correlate all'HPV, cancro e malattie infettive. L'azienda prevede di rendere disponibile l'abstract sul suo sito web dopo la presentazione, fornendo approfondimenti sul loro approccio innovativo che utilizza la tecnologia di elettroporazione CELLECTRA® per gli anticorpi codificati da DNA.
INOVIO (NASDAQ:INO), una empresa biotecnológica especializada en medicamentos de ADN, ha anunciado su participación en el World Congress of Electroporation el 18 de septiembre de 2024, en Roma, Italia. Trevor Smith, VP de I+D preclínica de INOVIO, realizará una presentación oral titulada 'Desarrollo de anticuerpos sintéticos codificados por ADN lanzados in vivo utilizando la tecnología de electroporación CELLECTRA®' a las 15:20 CET.
Esta presentación se alinea con el enfoque de INOVIO en el desarrollo de medicamentos de ADN para enfermedades relacionadas con el HPV, cáncer y enfermedades infecciosas. La empresa planea hacer disponible el resumen en su sitio web después de la presentación, proporcionando información sobre su enfoque innovador utilizando la tecnología de electroporación CELLECTRA® para anticuerpos codificados por ADN.
INOVIO (NASDAQ:INO)는 DNA 의약품 전문 생명공학 회사로서, 세계 전기천공 학회에 2024년 9월 18일 이탈리아 로마에서 참가할 예정이라고 발표했습니다. INOVIO의 선임 부사장인 Trevor Smith는 3:20 CET에 'CELLECTRA® 전기천공 기술을 이용한 생체 내 출시 합성 DNA 인코딩 항체 개발'이라는 제목으로 구두 발표를 하게 됩니다.
이번 발표는 INOVIO가 HPV 관련 질병, 암 및 감염병을 위한 DNA 의약품 개발에 집중하고 있다는 점과 일치합니다. 회사는 발표 후 자사의 웹사이트에서 초록을 제공할 예정이며, DNA 인코딩 항체를 위한 CELLECTRA® 전기천공 기술을 사용한 혁신적인 접근 방식에 대한 통찰을 제공할 것입니다.
INOVIO (NASDAQ:INO), une entreprise biotechnologique spécialisée dans les médicaments à base d'ADN, a annoncé sa participation au World Congress of Electroporation le 18 septembre 2024, à Rome, Italie. Trevor Smith, VP de la R&D préclinique chez INOVIO, fera une présentation orale intitulée 'Développement d'anticorps synthétiques codés par ADN lancés in vivo utilisant la technologie d'électroporation CELLECTRA®' à 15h20 CET.
Cette présentation s'inscrit dans l'engagement d'INOVIO à développer des médicaments à base d'ADN pour les maladies liées au HPV, le cancer et les maladies infectieuses. L'entreprise prévoit de rendre le résumé disponible sur son site web après la présentation, fournissant des informations sur son approche innovante utilisant la technologie d'électroporation CELLECTRA® pour les anticorps codés par ADN.
INOVIO (NASDAQ:INO), ein biotechnologisches Unternehmen, das sich auf DNA-Medikamente spezialisiert hat, hat seine Teilnahme am World Congress of Electroporation am 18. September 2024 in Rom, Italien angekündigt. Trevor Smith, VP der präklinischen Forschung und Entwicklung bei INOVIO, wird um 15:20 Uhr MEZ einen Vortrag mit dem Titel 'Entwicklung von in vivo eingesetzten, synthetischen DNA-kodierten Antikörpern unter Verwendung der CELLECTRA®-Elektroporationstechnologie' halten.
Diese Präsentation steht im Einklang mit INOVIOs Fokussierung auf die Entwicklung von DNA-Medikamenten für HPV-assoziierte Krankheiten, Krebs und Infektionskrankheiten. Das Unternehmen plant, die Zusammenfassung nach der Präsentation auf seiner Website zur Verfügung zu stellen und Einblicke in seinen innovativen Ansatz zur Verwendung der CELLECTRA®-Elektroporationstechnologie für DNA-kodierte Antikörper zu bieten.
- None.
- None.
World Congress of Electroporation
Oral Presentation by Trevor Smith, VP of Preclinical R&D at INOVIO
Abstract Title: Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA® electroporation technology
Date and Time: September 18, 2024, 3:20pm – 3:35pm CET
Location:
The abstract from the conference will be made available on INOVIO's website following the data presentation.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conference-302250936.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
What scientific conference is INOVIO (INO) presenting at in September 2024?
Who is presenting on behalf of INOVIO (INO) at the World Congress of Electroporation?
What is the title of INOVIO's (INO) presentation at the World Congress of Electroporation?
When and where will INOVIO (INO) make the abstract from the conference available?
What are the main areas of focus for INOVIO's (INO) DNA medicines?
